A tuberculosis serum marker screening method and application
Through the combination of bionic affinity chromatography and mass spectrometry, the problems of inadequate expression and false positive in tuberculosis serum marker screening were solved, the specificity and detection accuracy of serum markers were improved, and efficient tuberculosis diagnosis was achieved.
Patent Information
- Application Number
- CN202111432830.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-11-29
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-11-29
AI Technical Summary
The prior art In the screening of tuberculosis serum markers, there are problems such as insufficient protein expression, time-consuming and laborious purification of recombinant proteins, host-affected activity, and non-specific binding, resulting in false positive problems.
Using bionic affinity or affinity chromatography to specifically adsorb serum antibodies, antigen-antibody specific recognition, mass spectrometry analysis and bioinformatic analysis, the serum markers of tuberculosis were screened, and the biomimetic affinity chromatography and liquid chromatography-mass spectrometry were analyzed. and immunologic verification to build a tuberculosis serum marker library to improve diagnostic accuracy.
The preparation of high-purity serum antibodies is achieved, the specificity and detection sensitivity of tuberculosis serum markers are improved, non-specific binding interference is reduced, and diagnostic accuracy and efficiency are enhanced.
Smart Images

Figure CN114235990B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of medical diagnosis, and in particular to a method for screening tuberculosis serum markers and application of the method in the field of tuberculosis serum diagnosis. Background Art
[0002] Tuberculosis (TB) is one of the infectious diseases with the highest mortality rate caused by Mycobacterium tuberculosis (MTB). Pulmonary tuberculosis patients account for 90% of the total number of patients. The current research on serum markers for tuberculosis is a separate and non-specific research model with the following limitations: (1) About 50% of Mycobacterium tuberculosis (MTB) proteins cannot be expressed in exogenous Escherichia coli (E. coli) host cells, resulting in the omission of such proteins in serum marker screening. (2) The expression and separation and purification of a large number of MTB recombinant proteins is time-consuming and labor-intensive, and most of the recombinantly expressed proteins are not ideal serum markers. (3) The activity of exogenously expressed MTB proteins is easily affected by the properties of the expression host itself; (4) The total serum of the patient is used to identify MTB proteins. Since the composition of the whole serum protein is very complex, there is a high possibility of non-specific binding, which can easily lead to false positive test results.
[0003] In order to solve the limitations of the existing technology for screening tuberculosis serum markers, an effective screening method is needed. Summary of the invention
[0004] The present invention discloses a method for screening tuberculosis serum markers, which combines biomimetic affinity or affinity chromatography to specifically adsorb serum antibodies, antigen (tuberculosis antigen)-antibody specific recognition, mass spectrometry analysis, and bioinformatics analysis methods to achieve high-throughput screening of tuberculosis patient serum markers, thereby overcoming the limitations of the prior art method for screening tuberculosis serum markers.
[0005] In addition, the invention also discloses the application of the screening method, which improves the diagnosis accuracy of tuberculosis.
[0006] In order to achieve the above object, the present invention adopts the following technical solutions:
[0007] A method for screening tuberculosis serum markers comprises the following steps:
[0008] a. subjecting the serum protein of the experimental group to bionic affinity or affinity chromatography to prepare a bionic affinity or affinity chromatography antibody column for the experimental group; subjecting the serum protein of the control group to bionic affinity or affinity chromatography to prepare a bionic affinity or affinity chromatography antibody column for the control group;
[0009] b. preparing tubercle bacillus culture filtrate protein or tubercle bacillus cytoplasm protein, and respectively performing chromatography on the tubercle bacillus culture filtrate or tubercle bacillus cytoplasm protein with the bionic affinity or affinity antibody chromatography column of the experimental group, and performing chromatography on the bionic affinity chromatography column or affinity chromatography column of the control group with the same tubercle bacillus protein sample;
[0010] c. Eluting the chromatography column after step b is completed, and then performing liquid chromatography-mass spectrometry analysis on the eluted components;
[0011] d. Analyze the Mycobacterium tuberculosis culture filtrate or Mycobacterium tuberculosis cytoplasmic proteins bound to serum antibodies in the experimental group and the control group by liquid chromatography-mass spectrometry.
[0012] e. Search the Mycobacterium tuberculosis proteomics database to obtain the basic biochemical information of each specific protein; compare the Mycobacterium tuberculosis culture filtrate or Mycobacterium tuberculosis cytoplasm protein bound to the experimental group with the Mycobacterium tuberculosis protein bound to the control group, deduct the Mycobacterium tuberculosis protein bound to the control group, and finally construct a Mycobacterium tuberculosis serum marker protein library;
[0013] f. Perform mass spectrometry data analysis, bioinformatics analysis and immunological analysis on the proteins in the constructed tuberculosis serum marker library to obtain tuberculosis serum markers.
[0014] Furthermore, after the proteins in the tuberculosis serum marker library obtained in step f are expressed and separated and purified by genetic engineering, they are then evaluated using an immunological method of antigen-antibody specific recognition, which includes but is not limited to an indirect enzyme-linked immunosorbent assay (ELISA) to verify the sensitivity and specificity of the screened tuberculosis serum markers.
[0015] The serum of the experimental group of the present invention comes from tuberculosis patients, and the serum of the control group comes from healthy people undergoing physical examinations.
[0016] The biomimetic affinity materials used in the affinity chromatography of the experimental group and the control group in step a include, but are not limited to, any one or two of the following small molecule compounds: L-theanine; aminopyrine; 3-aminophenol; 4-amino-1-naphthol hydrochloride; 4-2-aminoethylbenzenesulfonamide; 1-aminoanthraquinone; hexylamine; 2,6-diaminoanthraquinone; 2,6-diaminopyridine; 2-phenylacetylamine; adenine; hydroxysuccinimide; 2,4,6-triaminopyrimidine; diphenylamine; dodecylamine; diethylamine hydrochloride; dibenzylamine; dodecylamine; N-acetyl-L-methionine. Or an affinity ligand for specific adsorption of serum antibodies, which is derived from Protein A (SPA) protein isolated or recombinantly expressed from type A Staphylococcus aureus, or Protein G isolated or recombinantly expressed from type G Streptococcus as an affinity ligand, is used to prepare an affinity ligand for specific adsorption of serum antibodies.
[0017] Further, the preparation of the biomimetic affinity chromatography column in step a comprises the following steps:
[0018] a1. Using Sepharose as the matrix adsorption material, pretreatment of the solid matrix, activation reaction, and ligand coupling are performed to construct a biomimetic affinity separation material that specifically adsorbs serum antibodies;
[0019] The invention further comprises a biomimetic affinity separation material for specifically adsorbing serum antibodies, which is respectively coupled to a sepharose solid phase carrier activated by epoxy and having cyanuric chloride as a spacer arm;
[0020] Another scheme includes an affinity separation material with a specific adsorption antibody as a ligand coupled to a sepharose solid phase carrier after epoxy activation with cyanuric chloride as a spacer arm and natural or genetically modified Protein A (SPA) isolated or recombinantly expressed from type A Staphylococcus aureus, or Protein G isolated or recombinantly expressed from type G Streptococcus.
[0021] a2. Pretreat serum samples and respectively use bionic affinity or affinity antibody columns prepared from materials that specifically adsorb serum antibodies screened from a bionic affinity ligand library.
[0022] a3. Analyze the protein loading, purity and yield of serum samples in different biomimetic affinity or affinity antibody columns.
[0023] The tubercle bacillus culture filtrate or tubercle bacillus cytoplasmic protein used in step b of the present invention includes the culture filtrate protein and tubercle bacillus cell cytoplasmic protein when tubercle bacillus is cultured. Preferably, the prepared tubercle bacillus culture filtrate or cytoplasmic protein is chromatographed with the bionic affinity or affinity antibody column of the experimental group and the bionic affinity or affinity antibody column of the control group respectively. Further, the affinity chromatography column of the experimental group and the affinity chromatography column of the control group are bionic affinity antibody columns or affinity antibody columns. Further, the tubercle bacillus culture filtrate or cytoplasmic protein not adsorbed by the affinity chromatography column is washed. Then the affinity chromatography column completed with step b is eluted in two steps. Further, the serum antibody-tuberculosis protein complex obtained after step b is completed. The tubercle bacillus protein includes but is not limited to the tubercle bacillus culture filtrate protein or the tubercle bacillus cell cytoplasmic protein.
[0024] The protein concentration of different elution components is quantitatively analyzed by the BCA method. The concentration of all component proteins to be detected by mass spectrometry is processed to the optimal concentration suitable for mass spectrometry detection, such as between 2mg-10mg / mL by ultrafiltration concentration. The flow-through and elution components are digested with trypsin and further dried for mass spectrometry analysis.
[0025] The elution in step c comprises eluting using a two-step elution method. Further, the elution method comprises:
[0026] (1) The eluent used for the biomimetic affinity separation material is a glycine-hydrochloric acid buffer system with a salt ion concentration of 0.01-5.0 mol / L at pH 2.0-4.5, a phthalic acid-hydrochloric acid buffer system with a salt ion concentration of 0.01-5.0 mol / L at pH 2.0-4.5, and a citric acid-sodium citrate buffer system with a salt ion concentration of 0.01-5.0 mol / L at pH 2.0-4.5. The elution system is also suitable for the chromatography of affinity separation materials for specific purification of serum antibodies with Staphylococcus aureus protein A (SPA) or Protein G from group G streptococci as ligands.
[0027] (2) The eluent used for the biomimetic affinity separation material can also be a Tris (hydroxymethylaminomethane) (Tris) buffer system with a pH of 10.0-13.0 and a salt ion concentration of 0.01-5.0 mol.
[0028] Further, step e comprises the following steps:
[0029] The tuberculosis bacilli proteins detected by mass spectrometry and bound to the experimental group and the control group were searched in the database (http: / / www.uniprot.org / ); the tuberculosis bacilli proteins specifically adsorbed by the serum antibodies of the control group were eliminated, and the tuberculosis serum marker library was constructed using the tuberculosis bacilli proteins of the experimental group after elimination.
[0030] The selected Mycobacterium tuberculosis proteins are subjected to bioinformatics, proteomics and immunological analysis prediction and specific serum marker screening, and the preferred method of step f comprises the following steps:
[0031] (1) Analyze the molecular weight, isoelectric point, hydrophilicity, subcellular localization, whether the proteins in the Mycobacterium tuberculosis protein library are secreted proteins, and the possible secretion mode.
[0032] (2) Screening out proteins with high abundance, strong sequence specificity and strong immunogenicity in the Mycobacterium tuberculosis protein library as candidate markers for the tuberculosis serum markers of the present invention.
[0033] (3) The tuberculosis serum markers selected by the above-mentioned bionic affinity chromatography-mass spectrometry strategy or affinity chromatography-mass spectrometry strategy are recombinantly expressed in Escherichia coli, and the target protein is separated and purified to obtain a high-purity recombinant target protein; finally, the indirect ELISA method is used to evaluate the detection sensitivity and specificity of the recombinant tuberculosis protein in the serum of tuberculosis patients, and finally the tuberculosis serum markers described in the present invention are selected.
[0034] Furthermore, a method for detecting tuberculosis is provided, wherein the tuberculosis serum marker used is prepared according to the method of the present invention.
[0035] Furthermore, a tuberculosis detection kit is provided, characterized in that the tuberculosis serum marker used in the kit is prepared according to the method of the present invention.
[0036] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0037] 1. Purify high-purity serum antibodies: Use biomimetic affinity chromatography or affinity chromatography to make the serum antibodies of the experimental group and the control group have high purity (>90%), so there is less non-specific binding when specifically adsorbed with tuberculosis antigens, which reduces interference with subsequent analysis and the specificity of the selected tuberculosis serum markers is high.
[0038] 2. High antigen activity and close to the natural state: This screening system combines bionic affinity chromatography, antigen-antibody specific recognition, mass spectrometry analysis, and bioinformatics analysis methods; the serum antibodies specifically bind to a mixture of natural tuberculosis proteins, which have high biological activity, and the composition and abundance of tuberculosis bacilli proteins are closer to the natural growth of the bacteria.
[0039] 3. Mild reaction conditions: The conditions of the antigen-antibody affinity chromatography process in this system are mild (10 mM, pH = 7.4, including but not limited to PBS buffer system), and the ratio of the combined amount of tuberculosis antigen and patient serum antibody is closer to the in vivo environment. The tuberculosis serum markers screened by the method of the present invention have high sensitivity and accuracy in detecting tuberculosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 BiAC grouped SDS-PAGE of human serum immunoglobulin G (IgG); M is a protein marker, T0 and H0 are the original samples of tuberculosis patient serum and healthy control group serum after mixing, T1-T4 and H1-H4 are the flow-through samples of tuberculosis patient serum and healthy control group serum during the chromatography process, and T5 and T6 are the SDS-PAGE samples of tuberculosis patient serum and healthy control group serum eluted with 0.05 mol / L Gly-HCl solution at pH 2.5 during the chromatography process.
[0041] Figure 2 Flowchart of the present invention.
[0042] Figure 3 SDS-PAGE image of the recombinant protein after Mycobacterium tuberculosis protein was recombinantly expressed in the Escherichia coli system and separated and purified using Ni+ filler and molecular exclusion technology.
[0043] Figure 4 The sensitivity and specificity of the recombinant protein in the serum of tuberculosis patients were evaluated by ELISA. Specific embodiments
[0044] Preparation Example 1 Construction of a biomimetic affinity ligand library
[0045] The biomimetic affinity ligand synthesis process is similar to the content of our previously disclosed patent: "Antibody affinity purification materials and their uses, 2014.11.19, China, CN104148018A".
[0046] The biomimetic affinity small molecule structures for specific adsorption of human serum antibodies constructed this time include but are not limited to the following 19 types: L-theanine; aminopyrine; 3-aminophenol; 4-amino-1-naphthol hydrochloride; 4-2-aminoethylbenzenesulfonamide; 1-aminoanthraquinone; hexylamine; 2,6-diaminoanthraquinone; 2,6-diaminopyridine; 2-phenylacetamide; adenine; hydroxysuccinimide; 2,4,6-triaminopyrimidine; diphenylamine; dodecylamine; diethylamine hydrochloride; dibenzylamine; dodecylamine; N-acetyl-L-methionine.
[0047] The data of mixed serum samples of healthy control group separated and purified by biomimetic affinity medium A5-87 (5:4-2-aminoethylbenzenesulfonamide, 87:ethylenediamine) were taken as an example.
[0048] Take 5g of the system replaced with 10mM PBS, coupled with the biomimetic affinity ligand medium A5-87 of the small molecule compound 5:4-2 aminoethylbenzenesulfonamide and 87:ethylenediamine, and 10.5mL of the mixed healthy human serum with a concentration of 12.7mg / mL in a 50mL centrifuge tube, shake and mix for 30min at room temperature, and after standing for 10min, the above mixture and the biomimetic affinity medium are loaded into the gravity column, and the medium A5-87 is rinsed with 20 volumes of PBS, and the target protein bound to the medium is directly eluted with 0.05molGly-HClH, BCA protein quantification, SDS-PAGE electrophoresis, and the affinity protein purification effect is analyzed by grayscale scanning combined with BCA protein quantification data. The results show that the adsorption amount of the biomimetic affinity medium to the antibody is 16.3mg / mL, the purity of the target protein is 90.21%, and the overall protein yield is 87.21%.
[0049] Preparation Example 2 Sample pretreatment:
[0050] Experimental group: 20 tuberculosis patient serum samples were collected at 100 μL per sample, and a total of 2 mL of serum samples were obtained. The samples were centrifuged at 2000 rpm, the precipitate was discarded, and the serum was diluted 8 times with 0.005-0.5 mol PBS buffer.
[0051] Control group: Serum samples from 20 healthy people were taken and the treatment method was the same as that of the above experimental group.
[0052] Equilibration of biomimetic affinity chromatography column: The biomimetic affinity separation matrix gravity column was cleaned with 10 mL 0.1 M acetic acid, 10 mL double distilled water, 10 mL 0.1 M NaOH, and 10 mL double distilled water, respectively, and finally all chromatography columns were equilibrated with 10 mL PBS (10 mM, pH 7.4).
[0053] Bionic affinity chromatography of pretreated serum samples: 5 mL of diluted serum sample solutions of the experimental group and the control group were loaded, and the equilibrium chromatography column was washed with an excess of about 20 column volumes of PBS solution, and the penetration liquid was collected to prepare affinity chromatography columns of the experimental group and the control group.
[0054] SDS-PAGE analysis of human serum IgG biomimetic affinity chromatography (BiAC) grouping components:
[0055] The adsorbed proteins on the affinity chromatography columns of the experimental group and the control group were eluted with 10mL 50mM Gly-HCl (pH 2.5) and 0.05mol NaOH solution, and the adsorption effect of the biomimetic affinity chromatography column on the IgG antibodies in the serum of the experimental group and the control group was detected by 12.5% SDS-PAG gel electrophoresis. The protein sample solution to be tested was added with 5×SDS-PAGE loading buffer at a ratio of 4:1 (v / v), incubated in a 95℃ water bath for 10min, centrifuged at 12,000g for 5min, and the supernatant was taken for electrophoresis detection after cooling. The effect is as follows Figure 3 shown.
[0056] Column cleaning and preservation: The proteins bound to the affinity chromatography columns of the experimental group and the control group were cleaned with 10-20 mL of 0.5 mol NaOH solution, and the columns were washed with 20 mL of double distilled water. Finally, the biomimetic affinity chromatography columns were washed with 10 mL of 20% ethanol solution, and the affinity chromatography columns of the experimental group and the control group were preserved with 20% ethanol solution.
[0057] Example 1
[0058] like Figure 2 The process of the present invention is shown as follows. The prepared tubercle bacillus culture filtrate or tubercle bacillus cell cytoplasm protein is chromatographed with the experimental group bionic affinity chromatography column and the control group bionic affinity chromatography column respectively. The material of the experimental group bionic affinity chromatography column and the control group bionic affinity chromatography column is A5-87.
[0059] Liquid chromatography-mass spectrometry analysis of eluted fractions:
[0060] All eluted protein components of the control group and experimental group adsorbed on the biomimetic affinity chromatography column A5-87 by the biomimetic-immunoaffinity method were collected; and all eluted components were replaced with 25mM NH4HCO3 buffer system. Then all samples were hydrolyzed with Trypsin, and the hydrolyzed peptides were desalted by Ziptip, and the component concentration was adjusted to 0.01mg-10mg / mL, and then LC-MS / MS analysis was performed. The detected mass spectrum peak was injected online into the LTQ-VELOS mass spectrometer for ion identification of peptide fragments. The eluted components flowing out of the reverse phase chromatography column were sprayed by the nanoliter electrospray port (voltage of 1.9Kv), the ion transmission capillary temperature was 200℃, and the mass spectrum was full scan (Mass ranges, m / z: 350~1500). Twenty fragment spectra were collected from the mass spectrum fragment map after the full scan for secondary mass spectrometry scanning (MS2 scan).
[0061] Mass spectrometry data analysis and candidate protein standard setting:
[0062] MS / MS (secondary mass spectrometry) database search was performed using BioWorks TM The .raw file obtained after searching the proteomics database with Sequest of 3.1.6 software (default parameters) was converted into a .mgf file. In this study, the protein sequences in the Mycobacterium tuberculosis complex in the UNIPROT database were searched for each grouped component. The retrieval set the fixed modification of the peptide sequence amino acid to carbamidomethyl (C), the variable modification to Oxidation (M), and the mass deviation to 20ppm. Two deletions were allowed for the trypsin digestion fragment. The data filtering parameters were set as follows: XCorr ≥ 1.9, +1; XCorr ≥ 2.5, +2; XCorr ≥ 3.75, +3; ΔCn ≥ 0.1.
[0063] Analysis and prediction of basic biological functions of detected Mycobacterium tuberculosis proteins:
[0064] The information of the proteolytic polypeptide fragments of Mycobacterium tuberculosis detected by mass spectrometry can be compared with the polypeptide fragments of the whole protein of Mycobacterium tuberculosis cleaved by virtual enzyme digestion; finally, the basic information of the protein such as amino acid sequence, molecular weight, isoelectric point, etc. can be obtained from the UNIPROT database (http: / / www.uniprot.org / ). To further study the properties of the detected protein, SignalP v5.0 (http: / / www.cbs.dtu.dk / services / SignalP-5.0 / ) was used to analyze whether it had a signal peptide; Lipop v1.0 was used to analyze whether it was a lipoprotein; TatP v1.0 (http: / / www.cbs.dtu.dk / services / TatP / ) was used to analyze whether the protein was secreted into the external environment using the "TAT" model; GRAVY (http: / / www.bioinformatics.org / sms2 / protein_gravy.html) was used to evaluate its overall hydrophilicity; TMHMM (http: / / www.cbs.dtu.dk / services / TMHMM / ) software was used to analyze whether the detected protein was a transmembrane protein and the specific number of transmembrane proteins; Psortb v3.0 (http: / / www.psort.org / psortb / ) was used to analyze its subcellular location; and Functional groups (http: / / genolist.pasteur.fr / TubercuList / ) was used to analyze the functional type of the protein.
[0065] The recognition specificity between serum antibodies (healthy people, tuberculosis patients) specifically adsorbed on bionic affinity or affinity antibody columns and target antigens (tuberculosis culture filtrate proteins or tuberculosis cell cytoplasmic proteins) will be affected by the following factors: (1) the specific recognition between low-concentration antibodies in healthy people caused by BCG (live attenuated bovine tuberculosis vaccine) and tuberculosis antigens; (2) other non-pathogenic bacteria in the environment that have certain homology with tuberculosis stimulate the body to produce antibodies and tuberculosis proteins; (3) non-specific binding of antibodies in human serum to a small part of tuberculosis proteins; (4) non-specific binding between bionic affinity fillers themselves and tuberculosis proteins. The theoretical probability of this situation depends on the choice of the final detection tool. If ELISA or Western-blot methods are used, the above non-specific proteins may not be effectively obtained; if high-sensitivity mass spectrometry is used, the detection rate of the above non-specific proteins will be enhanced. Therefore, setting reasonable screening criteria can reduce the interference factors in the judgment of experimental results to a certain extent.
[0066] Mass spectrometry was used to analyze the proteomic information of tuberculosis proteins recognized by serum antibodies of tuberculosis patients or serum antibodies of healthy controls. The tuberculosis antigen-serum antibody complex was searched against the tuberculosis proteomics database and the human proteomics database (to evaluate the adsorption effect of biomimetic affinity or affinity filler on antibodies). The following screening criteria were set for the tuberculosis protein information obtained by searching the tuberculosis proteomics database: (1) One or more peptide sequences that specifically bind to the serum antibodies of tuberculosis patients were used to identify the tuberculosis complex protein and preliminarily included it in the candidate biomarker range; (2) Whether the tuberculosis antigens that bind to both the serum antibodies of tuberculosis patients and the serum antibodies of healthy people were listed as candidate serum markers; this depended on the mass spectrometry detection data results of the same protein detected in the experimental group and the control group. If the number of peptides detected by mass spectrometry to identify the same protein in the two components was equal to or had no significant difference in the coverage of the peptide sequences, the protein could not be used as a component of the tuberculosis serum marker antigen library; otherwise, the tuberculosis protein was listed as a candidate serum marker for tuberculosis detection.
[0067] Based on the above criteria, 237 tuberculosis proteins shown in Table 1 were finally detected as preliminary tuberculosis serological markers; a large number of candidate proteins that have been used as tuberculosis serological detection and vaccine research: PstSI (38kda), FbpB, FbpC, FbpA, Hspx, BfrB, EsxA, EsxB Mtp63 and Mpt64 were all screened out.
[0068] Table 1: List of tuberculosis proteins recognized by serum antibodies of tuberculosis patients
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076] Based on the biomimetic-immunoaffinity chromatography-mass spectrometry strategy, the tuberculosis protein that specifically identifies the serum of tuberculosis patients is screened. With the help of bioinformatics and immunology knowledge, some candidate proteins are eliminated according to the following standards to save costs and improve the efficiency of biomarker verification. Screening method:
[0077] (1) Selecting high-abundance tuberculosis proteins that bind to tuberculosis patient serum, wherein the preferred protein feature is that the number of protein peptides detected by mass spectrometry is greater than 2, including but not limited to all tuberculosis proteins listed in Table 1.
[0078] (2) Based on the bioinformatics prediction of biochemical properties such as Mw, pI, GRAVY, TMDs, etc., proteins that are difficult to express in E. coli are eliminated. Such proteins mainly refer to MTB proteins with strong hydrophobicity (GRAVY>0.6); or extreme size (Mw<8kDa, or Mw>80kDa), and containing transmembrane domains (TMDs>1). In addition to the above two main screening criteria, the following criteria can be used as reference content for further optimization of tuberculosis serum marker screening strips.
[0079] (3) Preferably, only tuberculosis proteins with pathogenic mycobacteria (Region different, RD region) are present; thus, preferred proteins include but are not limited to tuberculosis proteins encoded by Rv3874, Rv3875, Rv1980, Rv3117, Rv1770 and Rv1771 genes.
[0080] (4) Secretory proteins that bind to tuberculosis patient sera and proteins that have been confirmed as virulence factors are preferred; preferred proteins include but are not limited to Mycobacterium tuberculosis virulence factor proteins identified in bioinformatics analysis and published articles.
[0081] (5) Optimizing subcellular localization analysis results: selecting in the order of secretory proteins > cell wall proteins > cell membrane proteins > cytoplasmic proteins; thus, secretory proteins and cell wall proteins are preferred.
[0082] (6) Using the Basic Local Alignment Search Tool (BLAST), the peptide sequences of the final selected Mycobacterium tuberculosis proteins were compared with those in the human proteomics database, and the Mycobacterium tuberculosis proteins with large differences were selected as biomarkers for serological detection of latent tuberculosis.
[0083] (7) Tuberculosis proteins that are easily expressed in E. coli are preferred; such proteins should have a Mw value of 10-60 kDa, a pI value of 4.5-10, and should not contain a transmembrane domain. In addition, the signal peptide sequence of the tuberculosis protein with a signal peptide should be removed during recombinant expression.
[0084] Based on the above criteria, the following 111 Mycobacterium tuberculosis proteins were screened out as candidate proteins for tuberculosis serum markers (by gene number): Rv0009, Rv0066c, Rv0118c, Rv0129c, Rv0144, Rv0147, Rv0164, Rv0172, Rv0211, Rv0234c, Rv0242c, Rv0243, Rv0315, Rv0350, Rv0363, Rv0440, Rv0462, Rv0467, Rv0475, Rv0524, Rv0569, Rv0577, Rv0685, Rv0733, Rv0761c, Rv0798c, Rv0814c, Rv0831c, Rv0860, Rv0864, Rv0871, Rv0896, Rv0932c, Rv0934, Rv0984, Rv1071c, Rv1074c, Rv1094, Rv11 33c,Rv1177,Rv1198,Rv1267c,Rv1308,Rv1310,Rv1324,Rv1352,Rv1392,Rv1438,Rv1448c,Rv1475c,Rv1630,Rv1633,Rv1643,Rv173 2. Rv1770, Rv1819c, Rv1827, Rv1837c, Rv1872c, Rv1876c, Rv1926c, Rv1932, Rv1980c, Rv2007c, Rv2030c, Rv2031c, Rv2166c, Rv2204 c, Rv2220, Rv2244, Rv2376c, Rv2383c, Rv2402, Rv2427c, Rv2462c, Rv2476c, Rv2557, Rv2589, Rv2626c, Rv2831, Rv2882c, Rv2889c, R v2945c, Rv2986c, Rv3006, Rv3028c, Rv3048c, Rv3049c, Rv3117, Rv3130c, Rv3139, Rv3248c, Rv3269, Rv3354, Rv3417c, Rv3418c, Rv3 457c, RV3497c, RV3568c, RV3596c, RV3597c, RV3763, RV3800c, RV3803c, RV3804, RV3841, RV3846, RV3874, RV3875, RV3914, RV3920c.
[0085] However, the workload of expressing and isolating and purifying more than one hundred Mycobacterium tuberculosis proteins in Escherichia coli is very large; the present invention randomly selected 20 Mycobacterium tuberculosis proteins, used Escherichia coli as the host bacteria for prokaryotic expression, and used nickel filler to separate and purify the recombinant proteins, and finally evaluated its sensitivity and specificity in the serum of tuberculosis patients (experimental group) and the serum of healthy people (control group).
[0086] (I) Prokaryotic expression and purification of candidate proteins
[0087] 1. Construction of recombinant expression vector
[0088] (1) Primer design and synthesis: Based on the MTB protein sequence number (Accession Number) that was specifically recognized by the serum of tuberculosis patients, the corresponding gene sequence of the protein was retrieved in the NCBI database. Then, bioinformatics methods were used to analyze whether the protein had a signal peptide, whether it was a transmembrane protein, and the overall hydrophobicity of the protein. When designing the final primers, the signal peptides of proteins with signal peptide sequences were removed, proteins with transmembrane domains, and proteins with large and small molecular weights (Mw>70kDa or Mw<10kDa) were eliminated; highly hydrophobic proteins containing transmembrane domains were eliminated; and 20 target genes were randomly screened. Finally, according to its gene sequence, the target gene was obtained by conventional primer design and polymerase chain reaction (PCR).
[0089] (2) Construction and expression of recombinant expression vector: The target gene obtained by PCR and the target vector PET28a were cut by the classic restriction endonuclease and connected by T4 DNA enzyme. The target gene was constructed on the expression vector PET28a. The Rv3875 gene expression protein was less than 10 kDa, so it was constructed on the expression vector PET32a containing the Trx protein. The target gene sequence was sequenced to verify whether it was successfully and correctly constructed. Finally, the verified correct recombinant expression vector was transformed into Escherichia coli BL21 (DE3) host cells for classic recombinant protein expression and verification. Finally, the recombinant proteins encoded by the following genes: Rv0475, Rv0577, Rv0871, Rv0934, Rv1980, Rv2031, Rv2462, Rv2831, Rv2986, Rv3048c, Rv3248c, Rv3417c, Rv3457, Rv3763 and Rv3875 were successfully recombined and expressed in Escherichia coli;
[0090] 2. Isolation and purification of recombinant expressed protein:
[0091] Each 1g of bacterial cells was fully resuspended in 15-30mL of 50mM Tris-HCl (pH8.0) buffer containing 20mM imidazole. The bacterial cells were disrupted by ultrasonication and centrifuged at 12,000rpm for 30min at 4°C. The supernatant was collected and finally filtered through a filter membrane with a pore size of 0.45μm to remove particulate matter.
[0092] If the recombinant protein exists in the host cell in the form of inclusion bodies, the bacteria are collected, and the protein precipitate is collected by centrifugation at 12,000rpm for 10min after ultrasonic disruption, and the recombinant protein is re-dissolved with 8M urea, centrifuged at 12,000rpm for 30min, and the precipitate is discarded. The supernatant is placed in a 3kDa dialysis bag and dialyzed with 7M, 6M, 5M, 4M, 3M and 2Mol / L urea solutions for renaturation. Finally, the recombinant MTB protein containing His-tag is purified by Ni+ metal chelate chromatography column. The recombinant protein is further desalted and purified by molecular exclusion chromatography (Superdex TM G75, GE), and its sensitivity and specificity in the serum of tuberculosis patients are detected by ELISA.
[0093] 3. ELISA method to evaluate the sensitivity and specificity of recombinant protein in the serum of tuberculosis patients
[0094] Sensitivity and specificity evaluation experiments were conducted in 198 samples of tuberculosis patient sera and 60 samples of healthy subjects: the purified recombinant protein was diluted to 1-5 μg / mL with 0.05 mmol / L carbonate buffer (pH 9.6), and 100 μL per well was coated on a 96-well plate, incubated overnight at 4°C, and washed five times on a plate washer with 1×PBST (10 mM PBS solution containing 0.5% Tween 20) washing buffer the next day; 300 μL of blocking solution containing 3% skimmed milk powder was added to each well and blocked at 37°C for 2 h, the plate was washed six times with PBST, and patted dry; 100 μL of blocking solution was added to each well with a spray gun, and 3-8 μL of serum samples from tuberculosis patients and the control group were added to the corresponding wells respectively. Incubate at 37°C for 1 hour, wash the 96-well plate 6 times; add 100 μL of HRP-labeled goat anti-human IgG polyclonal antibody diluted 5,000-10,000 times with PBST to each well, incubate at 37°C for 1 hour, wash the 96-well plate 6 times; add 100 μL of TMB substrate buffer to each well, incubate at 37°C for 10-30 minutes; add 50 μL of 2 mol / L H2SO4 solution to each well to terminate the reaction; measure the Abs value at a wavelength of 450nm with an enzyme reader to determine the experimental results (if the OD450 value of the sample to be tested is greater than the sum of the mean OD450 value of the negative control sample and its 3 times standard deviation, the sample to be tested is judged to be positive, and if it is lower than this value, it is judged to be negative;)
[0095] The results show that: Figure 4As shown, the sensitivity of the above-screened tuberculosis proteins detected in patient serum ranged from 37.12±1.31 (protein encoded by the Rv3763 gene) to 56.96±2.83 (protein encoded by the Rv0577 gene); the specificity ranged from 85.83±1.44 (protein encoded by the Rv3048c gene) to 96.67±1.77 (protein encoded by the Rv3248c gene).
Claims
1. A method for screening tuberculosis serum markers, characterized in that: The following steps are involved: a. subjecting the serum protein of the experimental group to bionic affinity or affinity chromatography to prepare a bionic affinity or affinity antibody chromatography column for the experimental group; subjecting the serum protein of the control group to bionic affinity or affinity chromatography to prepare a bionic affinity or affinity antibody chromatography column for the control group; b. Preparing tubercle bacillus culture filtrate protein or tubercle bacillus cytoplasm protein, respectively subjecting the tubercle bacillus culture filtrate or tubercle bacillus cytoplasm protein to affinity chromatography with a bionic affinity or affinity antibody column of an experimental group, and subjecting the same tuberculosis protein sample to affinity chromatography with a bionic affinity antibody column or affinity antibody column of a control group; after completing step b, a serum antibody-tuberculosis protein complex is obtained; c. The chromatography column after elution step b is completed; all eluted components are analyzed by liquid chromatography-mass spectrometry; d. analyzing the proteomic information of the culture filtrate of Mycobacterium tuberculosis or the cytoplasmic proteins of Mycobacterium tuberculosis in the experimental group and the control group by liquid chromatography-mass spectrometry; e. Search the Mycobacterium tuberculosis proteomics database to obtain the basic biochemical information of each protein; analyze and compare the differences between the Mycobacterium tuberculosis culture filtrate or Mycobacterium tuberculosis cytoplasm protein bound to the experimental group and the Mycobacterium tuberculosis protein bound to the control group, deduct the Mycobacterium tuberculosis protein bound to the serum antibody column of the control group, and select the Mycobacterium tuberculosis protein that specifically binds to the serum of tuberculosis patients as a serological detection marker for tuberculosis; f. Perform mass spectrometry data analysis, bioinformatics analysis and immunological analysis on the tuberculosis serum marker protein constructed in step e to obtain a tuberculosis serum marker.
2. A tuberculosis serum marker screening method according to claim 1, characterized in that: The small molecule functional ligands used in the bionic affinity chromatography performed on the experimental group and the control group in step a are: L-theanine; aminopyrine; 3-aminophenol; 4-amino-1-naphthol hydrochloride; 4-2-aminoethylbenzenesulfonamide; 1-aminoanthraquinone; hexylamine; 2,6-diaminoanthraquinone; 2,6-diaminopyridine; 2-phenylacetamide; adenine; hydroxysuccinimide; 2,4,6-triaminopyrimidine; diphenylamine; dodecylamine; diethylamine hydrochloride; dibenzylamine; N-acetyl-L-methionine, or a bionic affinity ligand that specifically adsorbs serum antibodies, or a combination of any two of the following.
3. A tuberculosis serum marker screening method according to claim 2, characterized in that: The elution in step c may be completed using a one-step or two-step elution method.
4. A tuberculosis serum marker screening method according to claim 3, characterized in that: The detection protein concentration is 0.01mg / mL-30mg / mL.
5. A tuberculosis serum marker screening method according to claim 4, characterized in that: The bioinformatics analysis in step f includes: one or more combinations of molecular weight, isoelectric point, hydrophilicity, subcellular localization, protein virulence factor, and protein epitope analysis.
6. A test kit for detecting tuberculosis, characterized in that: The tuberculosis serum marker used in the kit is prepared according to any one of the methods described in claims 1-5.
